Member Info for OAPK20

Wouldn’t want to be out of this over the weekend 😂😂

Looks like there’s still the remains of an overhang to clear before any significant rise. Anything over 2.1 sold into.

Personally I wouldn’t be surprised if the £500k loan facility is drawn down before CIZ sell any of their CDT holding.

Unless CDT releases news and heads for $20

Clive they did the same on the last to spikes. Raised it then shut sellers out with NT to sell. Low liquidity.

More updates to come. $1.8m staff costs with only 2 in the sales team leaves questions re affordability for expansion with current revenue without further funding.

CIZ tweeting

The CIZ1B Biomarker could be a major breakthrough in detecting lung cancer early, so this week we meet with our partners, iCCAMT, in Suzhou to progress our innovative diagnostic blood tests in this important market.

£300,000,000 per year

Over promised under delivered

30-40p range. Can’t see shareholders settling on any price less than £1.

Joe - “ Nasdaq will require us to file a new initial listing application and meet its initial listing requirements as opposed to its more lenient continued listing requirements. We cannot assure you that we will be able to meet those initial listing requirements at that time. ”

Still require confirmation of compliance.

On April 10, 2023, the Company received written notice (the “Notice”) from Nasdaq indicating that the Company is no longer in compliance with the minimum Market Value of Listed Securities (“MVLS”) of $50,000,000 required for continued listing on the Nasdaq Global Market (the “MVLS Requirement”). In accordance with Nasdaq rules, the Company has 180 calendar days, or until October 9, 2023 (the “Compliance Date”), to regain compliance with the MVLS Requirement. If, at any time before the Compliance Date, the market value of the Company’s listed securities closes at $50,000,000 or more for a minimum of 10 consecutive business days, Nasdaq will provide written notification to the Company that it has regained compliance with the MVLS Requirement. If the Company does not regain compliance with the MVLS Requirement by the Compliance Date, the Company will receive written notification that its securities are subject to delisting. At that time, the Company may appeal the delisting determination to a Nasdaq Listing Qualifications Panel. There can be no assurance that such appeal would be successful and Nasdaq would grant the Company’s request for continued listing. If the Company does not regain compliance with the MVLS Requirement by the Compliance Date, the Company may also be able to transfer the listing of its Class A Common Stock to the Nasdaq Capital Market, provided that the Company then meets the applicable requirements for continued listing on the Nasdaq Capital Market.

Additionally, in connection with our initial business combination, Nasdaq will require us to file a new initial listing application and meet its initial listing requirements as opposed to its more lenient continued listing requirements. We cannot assure you that we will be able to meet those initial listing requirements at that time.

If Nasdaq delists our securities from trading on its exchange, we could face significant material adverse consequences, including:

● inability to consummate our initial business combination;

● a limited availability of market quotations for our securities;

● reduced liquidity with respect to our securities;

● a determination that our shares of common stock are “penny stock” which will require brokers trading in our shares of common stock to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for our shares of common stock;

● a limited amount of news and analyst coverage for our company; and

● a decreased ability to issue additional securities or obtain additional financing in the future.

Put option value. £3.25M

Shares issued - 395,470 x $10 gives $3,954,700 - dollar to pound exchange rate - gives approx £ 3,243,146.95

CIZ need $10 a share or more for breakeven or profit. CDT Warrants are $11.50.

CIZ got the shares - “ at the same price per Conduit share that a proposed US$27 million private investment round in Conduit, led by new and existing investors of Conduit (the "PIPE Investment"), is to be effected at, as further described below.”

PIPE funding- “Immediately prior to completion of the Transaction, MURF closed the previously announced investment by a single institutional investor, which purchased $20.0 million of MURF’s units at a price of $10.00 per unit in a private placement. Each unit consisted of one share of common stock and one warrant to purchase one share of common stock (the “Offering”). The warrants have an exercise price of $11.50, are exercisable after 30 days after the completion of the business combination and expire five years after the completion of the Transaction. Together, the Transaction and the Offering, provide Conduit with approximately $20 million, after giving effect to Murphy Canyon stockholder redemptions and before payment of Transaction and Offering expenses.”

CIZ tweets.

1/4 - As a leading global #lifesciences company, @biotechne provide advanced #laboratory instrumentation and #reagents which has enabled us to meet key milestones in providing a #laboratory platform to develop our CIZ1B biomarker assay for early-stage lung cancer.

2/4 - #CIZ is now well placed to push forward its clinical trials programme in #USA to achieve an accredited #LDT. With a market cap in excess of $12billion and 3200 employees, Bio-Techne is the ideal partner for us to scale-up & distribute our solution globally.

3/4 - By using Bio-Techne’s ‘Simple Western’ platform, also known in the market as ‘Jess’, we will benefit from a fully automated, rigorous, quantitative, high-sensitivity platform using small sample input.

4/4 - In our pursuit of early cancer detection, we aim to work with leading industry partners in Life Science and Clinical Diagnostics Research such as Bio-Techne and bring life-saving innovation to market together.

Worth reading.

Extract- “The Ciz1 b-variant may be detected in a sample from a subject, for example a blood, urine, saliva or bronchoalveolar lavage sample.

In a preferred embodiment the sample is a blood sample from a subject. In a particularly preferred embodiment the sample is a plasma sample.

The Ciz1 b-variant may be detected by a method which comprises the following steps: a) capturing a fibrinogen/Ciz1 b-variant complex using a fibrinogen capture agent; and b) detecting Ciz1 b-variant using a Ciz1 b-variant detection agent; or a) capturing a fibrinogen/Ciz1 b-variant complex using a Ciz1 b-variant capture agent; and b) detecting fibrinogen using a fibrinogen detection agent.”

Also - “ For example, the step of enriching the exosomal fraction may comprise ultracentrifugation, ultrafiltration, continuous flow electrophoresis, chromatography or cross-flow ultrafiltration.

The cancer may be selected from lung, lymphoma, kidney, breast, liver, bladder, ovarian or thyroid cancer.

In particular, the cancer may be lung cancer.“

Patent History

Publication number: 20230266327

Type: Application

Filed: Mar 23, 2023

Publication Date: Aug 24, 2023

Inventor: Dawn Alison COVERLEY (Yorkshire)

Application Number: 18/188,958

Has Chris changed their name to Dan ? 😂

“Sorry for the perceived aggression it wasn’t my intent“

Accidental use of the shouty capitals 👍

Exactly Vince.

From the RNS

Variation to GBP500,000 Loan Facility

Pursuant to its facility agreement with E3 Fund SP (the "Investor") entered into on 20 September 2022 ("Facility") and amended on 21 April 2023, the Company and the Investor are pleased to announce they have agreed to vary the terms of the Facility to enable the Subscription to proceed at a premium to the fixed repayment price of the Facility of 1.8p per share.

The Facility has been extended until 8 December 2024 and will be drawable in tranches of not less than GBP100,000 as requested by the Company or the Investor. The first drawdown will be made available to the Company following Shareholder Approval at the Company's next General Meeting to allot a further 23,809,524 new Ordinary Shares. Repayment of the Facility is to be by way of issue and allotment of new Ordinary Shares in the capital of the Company at a new fixed price equal to the Issue Price of 2.1p per share ("Facility Shares").

Vince it hasn’t as far as I’m aware

23,809,524 @ 2.1p as per RNS. 🤷‍♂️

Is the potential in US $172,250,000 per annum?

No but if the investor decides to pump in £500K it’s a boost for CIZ and a sign of confidence from the investors they’ll get a return.

CIZ sp might be much higher if the facility is used by either party Joe

Might not be up to CIZ

“ and will be drawable in tranches of not less than GBP100,000 as requested by the Company or the Investor.”